Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVTX Travere Therapeutics, Inc.

盘后交易 06-24 16:00:54 EDT

57.69

+1.74

+3.11%

盘后57.69

+0.000.00%

16:00 EDT

最高57.85	最低56.02	成交量243.95万
今开56.55	昨收55.95	日振幅3.27%
总市值53.65亿	流通市值52.62亿	总股本9,299万
成交额1.39亿	换手率2.67%	流通股本9,122万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVTX","market":"US","secType":"STK","nameCN":"Travere Therapeutics, Inc.","latestPrice":57.69,"timestamp":1782331199999,"preClose":55.95,"halted":0,"volume":2439538,"hourTrading":{"tag":"盘后","latestPrice":57.69,"preClose":57.69,"latestTime":"16:00 EDT","volume":32935,"amount":1900020.15,"timestamp":1782331251074,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03109919571045567,"floatShares":91220000,"shares":92992905,"eps":-0.23036166,"marketStatus":"盘后交易","change":1.74,"latestTime":"06-24 16:00:54 EDT","open":56.55,"high":57.85,"low":56.02,"amount":139297561.251088,"amplitude":0.032708,"askPrice":58,"askSize":1,"bidPrice":56.6,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-0.23036166,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782345600000},"marketStatusCode":4,"adr":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":55.95,"preHourTrading":{"tag":"盘前","latestPrice":56.2,"preClose":55.95,"latestTime":"09:29 EDT","volume":812,"amount":45552.303552000005,"timestamp":1782307781051,"change":0.25,"changeRate":0.004468,"amplitude":0.01126},"postHourTrading":{"tag":"盘后","latestPrice":57.69,"preClose":57.69,"latestTime":"16:00 EDT","volume":32935,"amount":1900020.15,"timestamp":1782331251074,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.90861,"impliedVol":0.5676,"impliedVolPercentile":0.4183},"requestUrl":"/m/hq/s/TVTX","defaultTab":"news","newsList":[{"id":"1195726677","title":"Travere Therapeutics在2026年第63届欧洲肾脏协会大会上公布三期Duplex研究长期开放标签扩展数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1195726677","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195726677?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:10","pubTimestamp":1780582240,"startTime":"0","endTime":"0","summary":"Travere Therapeutics公司在2026年第63届欧洲肾脏协会大会上，正式发布了其关键性三期Duplex研究的长期开放标签扩展数据。这项研究旨在评估药物在罕见肾脏疾病患者中的持续疗效与安全性，其长期随访结果对于理解该疗法的持久性影响至关重要。公司此次公布的数据，为医学界提供了关于治疗长期效果的重要见解，可能对未来的临床实践产生深远影响。投资者与行业分析师正密切关注这些数据，因其直接关系到Travere Therapeutics核心产品的市场前景与监管审批路径。随着详细数据的披露，市场将能更全面地评估该疗法的潜力与风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181506700","title":"Travere Therapeutics与Everest Medicines就潜在同类最优BTK抑制剂Civorebrutinib达成独家许可协议 用于罕见肾病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1181506700","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181506700?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:01","pubTimestamp":1780398099,"startTime":"0","endTime":"0","summary":"Travere Therapeutics, Inc. 已与 Everest Medicines 就一款有望成为同类最优的布鲁顿酪氨酸激酶抑制剂 Civorebrutinib 达成独家许可协议。该药物旨在治疗罕见肾脏疾病，此次合作旨在加速该潜力疗法的开发和商业化进程，以应对未满足的临床需求。此举将整合两家公司的专业优势，共同推进这一创新药物的未来市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173466257","title":"Travere Therapeutics获美国专利商标局关于Filspari® (Sparsentan)治疗IgA肾病特定使用方法的专利申请许可通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1173466257","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173466257?lang=zh_cn&edition=full","pubTime":"2026-05-28 04:18","pubTimestamp":1779913126,"startTime":"0","endTime":"0","summary":"Travere Therapeutics, Inc. 宣布，其关于Filspari® (Sparsentan)用于治疗IgA肾病特定使用方法的专利申请，已获得美国专利商标局的许可通知。这一进展标志着公司在保护其创新疗法知识产权方面迈出了关键一步，为其在肾脏疾病治疗领域的持续发展提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167333102","title":"Travere Therapeutics增发4.75亿美元可转换优先票据 用于置换2029年到期可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1167333102","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167333102?lang=zh_cn&edition=full","pubTime":"2026-05-07 10:29","pubTimestamp":1778120961,"startTime":"0","endTime":"0","summary":"生物制药公司Travere Therapeutics近日宣布完成规模扩大的可转换优先票据发行，总额达4.75亿美元。此次发行为公司债务结构优化的重要举措，所筹资金将专项用于赎回2029年到期的现有可转换债券。可转换债券条款允许持有人在特定条件下将债券转换为公司普通股，此类融资工具在生物科技领域常被用于平衡股权稀释与资金需求。市场分析指出，此次增发规模超出初始计划，反映出投资者对该公司核心肾病疗法管线及长期增长前景的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182187974","title":"异动解读 | 分析师上调目标价，Travere Therapeutics盘中大涨5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182187974","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182187974?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:36","pubTimestamp":1777988160,"startTime":"0","endTime":"0","summary":"生物制药公司Travere Therapeutics (TVTX) 今日盘中股价大幅上涨5.99%，表现强劲。消息面上，根据路透报道，华尔街券商Leerink Partners将Travere Therapeutics的目标股价从50美元上调至55美元。分析师上调目标价通常被视为对公司未来前景的积极看法，这提振了市场信心，从而推动了股价上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100952042","title":"Piper Sandler将Travere Therapeutics评级上调至“增持”，目标价升至49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100952042","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100952042?lang=zh_cn&edition=full","pubTime":"2026-04-14 23:02","pubTimestamp":1776178932,"startTime":"0","endTime":"0","summary":"投资银行Piper Sandler宣布，将生物制药公司Travere Therapeutics的股票评级从“中性”上调至“增持”。与此同时，该机构将其目标股价从原先的38美元显著提升至49美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143391510","title":"Travere Therapeutics：Filspari获准用于降低无肾病综合征的8岁及以上FSGS成人与儿童患者的蛋白尿","url":"https://stock-news.laohu8.com/highlight/detail?id=1143391510","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143391510?lang=zh_cn&edition=full","pubTime":"2026-04-14 06:17","pubTimestamp":1776118672,"startTime":"0","endTime":"0","summary":"生物制药公司Travere Therapeutics宣布，其药物Filspari已获得监管批准，适用于治疗年龄在8岁及以上、未伴有肾病综合征的局灶节段性肾小球硬化症（FSGS）患者，旨在显著降低其蛋白尿水平。\n该适应症的获批为FSGS患者群体提供了新的治疗选择，尤其针对那些未发展为肾病综合征的成人与儿童患者。Filspari通过减少尿液中蛋白质的排泄，有望延缓疾病进展并改善患者的生活质量。\n此次批准基于临床试验数据，证实Filspari在目标人群中具有降低蛋白尿的有效性。公司表示将继续推进相关研究，以进一步评估该药物的长期疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120854292","title":"Travere Therapeutics公司Filspari适应症扩展 美国潜在适用人群超10万","url":"https://stock-news.laohu8.com/highlight/detail?id=1120854292","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120854292?lang=zh_cn&edition=full","pubTime":"2026-04-14 06:17","pubTimestamp":1776118642,"startTime":"0","endTime":"0","summary":"Travere Therapeutics公司宣布，其药物Filspari的适应症拓展已使美国潜在适用患者群体突破10万人。这一里程碑式的进展显著扩大了该疗法的市场覆盖范围，为更多患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514868388","title":"小摩：维持Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级, 目标价由42.00美元调整至44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514868388","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514868388?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:58","pubTimestamp":1740589098,"startTime":"0","endTime":"0","summary":"小摩：维持Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级, 目标价由42.00美元调整至44.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27005848413817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190867740","title":"异动解读 | Travere Therapeutics股价盘中大涨5.91% 投资者看好罕见肾病新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1190867740","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190867740?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:31","pubTimestamp":1740583910,"startTime":"0","endTime":"0","summary":"生物制药公司Travere Therapeutics股价当日盘中大涨5.91%,投资者对公司研发的罕见肾病新药sparsentan的前景看好。Travere Therapeutics专注于为患有罕见肾脏、肝脏和代谢疾病的人研发新药。其在研新药sparsentan是治疗局灶节段性肾小球硬化症和IgA肾病的后期候选药物,如果顺利获批上市,将为公司带来重大利好。虽然公司目前净利润为负,但营收和毛利较高,处于盈利前投入期正常状态。投资者看好sparsentan获批并推动公司业绩大幅增长的预期,推动了当日股价大涨超5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Travere Therapeutics股价盘中大涨5.91% 投资者看好罕见肾病新药前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514854832","title":"Travere Therapeutics, Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514854832?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:24","pubTimestamp":1740583442,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时24分，Travere Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Enveric Biosciences, Inc.、Athira Pharma, Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5090.48%、184.17%、177.50%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Organovo Holdings, Inc.，振幅分别为161.02%、39.47%、33.94%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226232403a2550337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226232403a2550337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514677689","title":"花旗：维持Travere Therapeutics(TVTX.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514677689","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514677689?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:25","pubTimestamp":1740414342,"startTime":"0","endTime":"0","summary":"花旗：维持Travere Therapeutics(TVTX.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至35.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25002548356350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513877337","title":"Travere Therapeutics, Inc.盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513877337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513877337?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:58","pubTimestamp":1740409101,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时58分，Travere Therapeutics, Inc.股票出现波动，股价大幅下挫5.09%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为148.73%、63.61%、25.10%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225821abdb1489&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225821abdb1489&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513375644","title":"Travere Therapeutics, Inc.2024财年实现净利润-3.21亿美元，同比增加14.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513375644","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513375644?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326471,"startTime":"0","endTime":"0","summary":"2月24日，Travere Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.21亿美元，同比增加14.63%；其中营业收入为2.33亿美元，同比增加60.69%，每股基本收益为-4.08美元。机构评级：截至2025年2月24日，当前有14家机构对Travere Therapeutics, Inc.目标价做出预测，其中目标均价为34.21美元，其中最低目标价为22.00美元，最高目标价为47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141a250ce13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141a250ce13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513136242","title":"坎托菲茨杰拉德公司：重申Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513136242","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513136242?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:34","pubTimestamp":1740159250,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22013448321042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TVTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778299","title":"Travere Therapeutics, Inc.盘中异动 股价大跌9.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778299?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Travere Therapeutics, Inc.股票出现波动，股价快速跳水9.92%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Acelyrin, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.10%、60.32%、17.96%，振幅较大的相关个股有Osr Holdings, Inc.、Gain Therapeutics, Inc.、Windtree Therapeutics, Inc.，振幅分别为11.30%、10.21%、7.29%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223115abd7af4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223115abd7af4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165114656","title":"Travere Therapeutics 第四季度调整后每股亏损 $-0.47 超预期，销售额 $7479万 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165114656","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165114656?lang=zh_cn&edition=full","pubTime":"2025-02-21 05:04","pubTimestamp":1740085466,"startTime":"0","endTime":"0","summary":"根据NASDAQ TVTX报道，Travere Therapeutics 公司报告了季度每股亏损 $-0.47，这一数据比分析师普遍预测的 $-0.56 高出 16.07%。相比去年同期每股亏损 $-0.94，有50%的上涨。相比去年同期的 $4506万，销售额增长了 65.98%。以上内容来自Benzinga Earnings专栏，原文如下：Travere $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 16.07 percent. This is a 50 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $74.79 million which beat the analyst consensus estimate of $73.34 ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510370128","title":"Evercore ISI Group：维持Travere Therapeutics(TVTX.US)评级，由优于大市调整至优于大市评级, 目标价由33.00美元调整至45.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510370128","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510370128?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370757,"startTime":"0","endTime":"0","summary":"Evercore ISI Group：维持Travere Therapeutics(TVTX.US)评级，由优于大市调整至优于大市评级, 目标价由33.00美元调整至45.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12223248121880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX","EVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510338744","title":"Travere Therapeutics, Inc.盘中异动 大幅上涨13.93%报24.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510338744?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:31","pubTimestamp":1739284264,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时31分，Travere Therapeutics, Inc.股票出现异动，股价大幅拉升13.93%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.92%。其相关个股中，Dominari Holdings Inc.、In8Bio, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.较为活跃，换手率分别为1857.07%、501.54%、169.16%，振幅较大的相关个股有In8Bio, Inc.、Dominari Holdings Inc.、Abpro Holdings, Inc，振幅分别为11.26%、8.44%、6.12%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223104a241fac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223104a241fac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510865602","title":"Travere Therapeutics, Inc.盘中异动 早盘股价大跌5.23%报20.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510865602?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:39","pubTimestamp":1739198378,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时39分，Travere Therapeutics, Inc.股票出现异动，股价急速下跌5.23%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为1911.49%、1022.03%、683.97%，振幅较大的相关个股有Soligenix, Inc.、Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.，振幅分别为103.16%、50.12%、34.46%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223938abc9a743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223938abc9a743&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TVTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://travere.com","stockEarnings":[{"period":"1week","weight":0.0481},{"period":"1month","weight":0.2593},{"period":"3month","weight":1.0301},{"period":"6month","weight":0.389},{"period":"1year","weight":2.8613},{"period":"ytd","weight":0.4643}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Travere Therapeutics, Inc.于2008年2月8日在俄克拉荷马州注册成立，并于2011年2月在特拉华州重新注册成立。Travere是一家总部位于加利福尼亚州圣地亚哥的综合性生物制药公司，致力于为患有罕见肾脏和代谢疾病的患者研发和提供改变生命的疗法。公司定期评估并酌情采取行动，通过产品许可和收购，拓展其产品线和已获批产品，以满足罕见病患者尚未得到充分满足的医疗需求，并挖掘公司认为具有良好增长潜力的领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.008601},{"month":2,"riseRate":0.615385,"avgChangeRate":0.073426},{"month":3,"riseRate":0.384615,"avgChangeRate":0.01408},{"month":4,"riseRate":0.461538,"avgChangeRate":-0.009817},{"month":5,"riseRate":0.538462,"avgChangeRate":0.020256},{"month":6,"riseRate":0.615385,"avgChangeRate":0.044099},{"month":7,"riseRate":0.5,"avgChangeRate":0.010273},{"month":8,"riseRate":0.5,"avgChangeRate":0.058304},{"month":9,"riseRate":0.416667,"avgChangeRate":0.007125},{"month":10,"riseRate":0.5,"avgChangeRate":0.033214},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03497},{"month":12,"riseRate":0.583333,"avgChangeRate":0.053144}],"exchange":"NASDAQ","name":"Travere Therapeutics, Inc.","nameEN":"Travere Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Travere Therapeutics, Inc.(TVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Travere Therapeutics, Inc.,TVTX,Travere Therapeutics, Inc.股票,Travere Therapeutics, Inc.股票老虎,Travere Therapeutics, Inc.股票老虎国际,Travere Therapeutics, Inc.行情,Travere Therapeutics, Inc.股票行情,Travere Therapeutics, Inc.股价,Travere Therapeutics, Inc.股市,Travere Therapeutics, Inc.股票价格,Travere Therapeutics, Inc.股票交易,Travere Therapeutics, Inc.股票购买,Travere Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Travere Therapeutics, Inc.(TVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}